Advertisement


Martin McCarter, MD, on Refinement of Surgical Treatment: Expert Perspective on ASCO’s 2020 Advance of the Year

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Martin McCarter, MD, of the University of Colorado Denver, discusses the recent strides in surgical oncology, how the role of surgery has changed, and what lies ahead for this staple of cancer therapy.



Related Videos

Gynecologic Cancers
Immunotherapy

Christopher B. Cole, MD, PhD, on Ovarian Cancer: First-in-Human Study of Interferon-Activated Autologous Monocytes

Christopher B. Cole, MD, PhD, of the National Cancer Institute, discusses findings from a phase I study of intraperitoneal monocytes activated by interferons alpha and gamma in patients with ovarian cancer. Two of 11 patients had a partial response and 5 of 11 had stable disease; ongoing efforts are exploring more immune system targets in order to increase efficacy (Abstract 1).

Pancreatic Cancer
Immunotherapy

Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).

Immunotherapy
Symptom Management
Skin Cancer

Kevin Tyan on Colitis Induced by Immune Checkpoint Inhibitors: Potential Preventive Strategy

Kevin Tyan, of Kinnos, and currently a medical school student at Harvard University, discusses his study findings, which showed that patients with melanoma who are treated with immunotherapy had a significantly lower risk of developing colitis if they also took vitamin D ( Abstract 89).

Skin Cancer
Immunotherapy

John N. Lukens, MD, on Advanced Melanoma: Antibiotics, Survival, and Colitis in Patients Receiving Immunotherapy

John N. Lukens, MD, of the Hospital of the University of Pennsylvania, discusses his finding that taking antibiotics within 3 months of starting treatment with immune checkpoint inhibitors may lead to inferior overall survival in patients with stage III or IV melanoma. The antibiotics were also linked to a higher incidence of severe immune-mediated colitis (Abstract 56).

Skin Cancer
Immunotherapy

Philippa G. Corrie, PhD, on Patient Outcomes in Melanoma After Immune Checkpoint Inhibition

Philippa G. Corrie, PhD, of Cambridge University Hospitals NHS Foundation Trust, discusses a review of 2,322 patients with metastatic melanoma receiving first-line immune checkpoint inhibitors as standard of care in England between 2014 and 2018 (Abstract 55).

Advertisement

Advertisement



Advertisement